CARMAT Takeover and Reorganization: Restructuring Procedure

CARMAT, a company specializing in the development of artificial hearts, has provided an update on its receivership proceedings. The Versailles Commercial Court approved a takeover bid on December 1, 2025. This bid proposes a plan to transfer CARMAT SA to CARMAT SAS, a newly formed entity controlled by LOHAS, itself headed by Pierre Bastid.

CARMAT SAS's new strategy focuses on expansion in North America and the launch of a clinical trial for the target therapy indication in Europe. The transition includes the retention of 88 employees and a reduction in expenses. €110 million in financing is planned, primarily from LOHAS and Sante Holdings. However, this acquisition will lead to the liquidation of CARMAT SA and the delisting of its shares from the Euronext Growth Paris stock exchange, resulting in the likely loss of investments for shareholders.